Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　― Results From the K-STAR Study ―-Reference-Cited by-同舟云学术

Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　― Results From the K-STAR Study ―

Published:2018 Issue:1 Volume:82 Page:159-167
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Inomata Takayuki¹,Ikeda Yuki²,Kida Keisuke³,Shibagaki Yugo⁴,Sato Naoki⁵,Kumagai Yuji⁶,Shinagawa Hisahito²,Ako Junya²,Izumi Tohru⁷,

Affiliation:

1. Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital

2. Department of Cardiovascular Medicine, Kitasato University

3. Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine

4. Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine

5. Internal Medicine and Cardiology, Nippon Medical School Musashi-Kosugi Hospital

6. Kitasato Academic Research Organization, Kitasato University

7. Niigata Minami Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/82/1/82_CJ-17-0179/_pdf

Reference32 articles.

1. 1. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. Eur Heart J 2013; 34: 835–843.

2. 2. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132–143.

3. 3. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, et al. Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014; 7: 261–270.

4. 4. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 2014; 20: 392–399.

5. 5. Krämer BK, Schweda F, Kammerl M, Riegger GA. Diuretic therapy and diuretic resistance in cardiac failure. Nephrol Dial Transplant 1999; 14(Suppl 4): 39–42.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis;Frontiers in Cardiovascular Medicine;2024-05-30

2. Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry;Heart and Vessels;2024-05-07

3. How should we treat acute kidney injury caused by renal congestion?;Kidney Research and Clinical Practice;2023-07-31

4. 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis;ACTA CARDIOL SIN;2023

5. Tolvaptan’s Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure;American Journal of Nephrology;2023-06-29